Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Onchocerciasis Market

ID: MRFR/Pharma/36981-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026

Onchocerciasis Market Research Report: Size, Share, Trend Analysis By Treatment Type (Medication, Surgical Intervention, Supportive Care), By End Users (Hospitals, Clinics, Research Institutions), By Distribution Channel (Direct Procurement, Pharmacies, Online Platforms), By Pathogen Type (Onchocerca volvulus, Other) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Type (USD Million)
      1. 4.1.1 Medication
      2. 4.1.2 Surgical Intervention
      3. 4.1.3 Supportive Care
    2. 4.2 Healthcare, BY End User (USD Million)
      1. 4.2.1 Hospitals
      2. 4.2.2 Clinics
      3. 4.2.3 Research Institutions
    3. 4.3 Healthcare, BY Distribution Channel (USD Million)
      1. 4.3.1 Direct Procurement
      2. 4.3.2 Pharmacies
      3. 4.3.3 Online Platforms
    4. 4.4 Healthcare, BY Pathogen Type (USD Million)
      1. 4.4.1 Onchocerca volvulus
      2. 4.4.2 Other
    5. 4.5 Healthcare, BY Region (USD Million)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Merck & Co. (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Boehringer Ingelheim (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 GlaxoSmithKline (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sanofi (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Novartis (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Pfizer (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Bristol-Myers Squibb (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY TYPE
    4. 6.4 US MARKET ANALYSIS BY END USER
    5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 US MARKET ANALYSIS BY PATHOGEN TYPE
    7. 6.7 CANADA MARKET ANALYSIS BY TYPE
    8. 6.8 CANADA MARKET ANALYSIS BY END USER
    9. 6.9 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    10. 6.10 CANADA MARKET ANALYSIS BY PATHOGEN TYPE
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY TYPE
    13. 6.13 GERMANY MARKET ANALYSIS BY END USER
    14. 6.14 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    15. 6.15 GERMANY MARKET ANALYSIS BY PATHOGEN TYPE
    16. 6.16 UK MARKET ANALYSIS BY TYPE
    17. 6.17 UK MARKET ANALYSIS BY END USER
    18. 6.18 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    19. 6.19 UK MARKET ANALYSIS BY PATHOGEN TYPE
    20. 6.20 FRANCE MARKET ANALYSIS BY TYPE
    21. 6.21 FRANCE MARKET ANALYSIS BY END USER
    22. 6.22 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    23. 6.23 FRANCE MARKET ANALYSIS BY PATHOGEN TYPE
    24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE
    25. 6.25 RUSSIA MARKET ANALYSIS BY END USER
    26. 6.26 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    27. 6.27 RUSSIA MARKET ANALYSIS BY PATHOGEN TYPE
    28. 6.28 ITALY MARKET ANALYSIS BY TYPE
    29. 6.29 ITALY MARKET ANALYSIS BY END USER
    30. 6.30 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    31. 6.31 ITALY MARKET ANALYSIS BY PATHOGEN TYPE
    32. 6.32 SPAIN MARKET ANALYSIS BY TYPE
    33. 6.33 SPAIN MARKET ANALYSIS BY END USER
    34. 6.34 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    35. 6.35 SPAIN MARKET ANALYSIS BY PATHOGEN TYPE
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY END USER
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATHOGEN TYPE
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY TYPE
    42. 6.42 CHINA MARKET ANALYSIS BY END USER
    43. 6.43 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    44. 6.44 CHINA MARKET ANALYSIS BY PATHOGEN TYPE
    45. 6.45 INDIA MARKET ANALYSIS BY TYPE
    46. 6.46 INDIA MARKET ANALYSIS BY END USER
    47. 6.47 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    48. 6.48 INDIA MARKET ANALYSIS BY PATHOGEN TYPE
    49. 6.49 JAPAN MARKET ANALYSIS BY TYPE
    50. 6.50 JAPAN MARKET ANALYSIS BY END USER
    51. 6.51 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    52. 6.52 JAPAN MARKET ANALYSIS BY PATHOGEN TYPE
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY END USER
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATHOGEN TYPE
    57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE
    58. 6.58 MALAYSIA MARKET ANALYSIS BY END USER
    59. 6.59 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    60. 6.60 MALAYSIA MARKET ANALYSIS BY PATHOGEN TYPE
    61. 6.61 THAILAND MARKET ANALYSIS BY TYPE
    62. 6.62 THAILAND MARKET ANALYSIS BY END USER
    63. 6.63 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    64. 6.64 THAILAND MARKET ANALYSIS BY PATHOGEN TYPE
    65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE
    66. 6.66 INDONESIA MARKET ANALYSIS BY END USER
    67. 6.67 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    68. 6.68 INDONESIA MARKET ANALYSIS BY PATHOGEN TYPE
    69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE
    70. 6.70 REST OF APAC MARKET ANALYSIS BY END USER
    71. 6.71 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    72. 6.72 REST OF APAC MARKET ANALYSIS BY PATHOGEN TYPE
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE
    75. 6.75 BRAZIL MARKET ANALYSIS BY END USER
    76. 6.76 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    77. 6.77 BRAZIL MARKET ANALYSIS BY PATHOGEN TYPE
    78. 6.78 MEXICO MARKET ANALYSIS BY TYPE
    79. 6.79 MEXICO MARKET ANALYSIS BY END USER
    80. 6.80 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    81. 6.81 MEXICO MARKET ANALYSIS BY PATHOGEN TYPE
    82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE
    83. 6.83 ARGENTINA MARKET ANALYSIS BY END USER
    84. 6.84 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    85. 6.85 ARGENTINA MARKET ANALYSIS BY PATHOGEN TYPE
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATHOGEN TYPE
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY END USER
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATHOGEN TYPE
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY END USER
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATHOGEN TYPE
    99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE
    100. 6.100 REST OF MEA MARKET ANALYSIS BY END USER
    101. 6.101 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    102. 6.102 REST OF MEA MARKET ANALYSIS BY PATHOGEN TYPE
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
    111. 6.111 HEALTHCARE, BY END USER, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
    113. 6.113 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    115. 6.115 HEALTHCARE, BY PATHOGEN TYPE, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY PATHOGEN TYPE, 2024 TO 2035 (USD Million)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY END USER, 2025-2035 (USD Million)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.2.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.3.2 BY END USER, 2025-2035 (USD Million)
      3. 7.3.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.3.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.4.2 BY END USER, 2025-2035 (USD Million)
      3. 7.4.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.4.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.5.2 BY END USER, 2025-2035 (USD Million)
      3. 7.5.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.5.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.6.2 BY END USER, 2025-2035 (USD Million)
      3. 7.6.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.6.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.7.2 BY END USER, 2025-2035 (USD Million)
      3. 7.7.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.7.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.8.2 BY END USER, 2025-2035 (USD Million)
      3. 7.8.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.8.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.9.2 BY END USER, 2025-2035 (USD Million)
      3. 7.9.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.9.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.10.2 BY END USER, 2025-2035 (USD Million)
      3. 7.10.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.10.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.11.2 BY END USER, 2025-2035 (USD Million)
      3. 7.11.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.11.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.12.2 BY END USER, 2025-2035 (USD Million)
      3. 7.12.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.12.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.13.2 BY END USER, 2025-2035 (USD Million)
      3. 7.13.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.13.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.14.2 BY END USER, 2025-2035 (USD Million)
      3. 7.14.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.14.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.15.2 BY END USER, 2025-2035 (USD Million)
      3. 7.15.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.15.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.16.2 BY END USER, 2025-2035 (USD Million)
      3. 7.16.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.16.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.17.2 BY END USER, 2025-2035 (USD Million)
      3. 7.17.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.17.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.18.2 BY END USER, 2025-2035 (USD Million)
      3. 7.18.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.18.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.19.2 BY END USER, 2025-2035 (USD Million)
      3. 7.19.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.19.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.20.2 BY END USER, 2025-2035 (USD Million)
      3. 7.20.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.20.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.21.2 BY END USER, 2025-2035 (USD Million)
      3. 7.21.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.21.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.22.2 BY END USER, 2025-2035 (USD Million)
      3. 7.22.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.22.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.23.2 BY END USER, 2025-2035 (USD Million)
      3. 7.23.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.23.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.24.2 BY END USER, 2025-2035 (USD Million)
      3. 7.24.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.24.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.25.2 BY END USER, 2025-2035 (USD Million)
      3. 7.25.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.25.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.26.2 BY END USER, 2025-2035 (USD Million)
      3. 7.26.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.26.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.27.2 BY END USER, 2025-2035 (USD Million)
      3. 7.27.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.27.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.28.2 BY END USER, 2025-2035 (USD Million)
      3. 7.28.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.28.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.29.2 BY END USER, 2025-2035 (USD Million)
      3. 7.29.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.29.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.30.2 BY END USER, 2025-2035 (USD Million)
      3. 7.30.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.30.4 BY PATHOGEN TYPE, 2025-2035 (USD Million)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Million, 2025-2035)

  • Medication
  • Surgical Intervention
  • Supportive Care

Healthcare By End User (USD Million, 2025-2035)

  • Hospitals
  • Clinics
  • Research Institutions

Healthcare By Distribution Channel (USD Million, 2025-2035)

  • Direct Procurement
  • Pharmacies
  • Online Platforms

Healthcare By Pathogen Type (USD Million, 2025-2035)

  • Onchocerca volvulus
  • Other

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions